Multiple Sclerosis and Related Disorders

Serum neurofilament levels are associated with health outcomes and resource use in MS 1:34
Serum neurofilament levels are associated with health outcomes and resource use in MS
Tanuja Chitnis • 23 Feb 2021
ACTRIMS highlights: aging, emerging concepts, and visual pathways 1:13
ACTRIMS highlights: aging, emerging concepts, and visual pathways
Elias Sotirchos • 23 Feb 2021
Funding clinical studies in Latin America 1:28
Funding clinical studies in Latin America
Fernando Hamuy Diaz de Bedoya • 15 Feb 2021
Assessing novel biomarkers: retinal layer atrophy in PMS vs. RRMS 2:28
Assessing novel biomarkers: retinal layer atrophy in PMS vs. RRMS
Elias Sotirchos • 23 Feb 2021
No evidence of disease activity as a predictive measure of long-term disability in RRMS 2:51
No evidence of disease activity as a predictive measure of long-term disability in RRMS
Dalia Rotstein • 16 Feb 2021
MS disease stage modulates the relationship between serum neurofilament light and age 1:45
MS disease stage modulates the relationship between serum neurofilament light and age
Tanuja Chitnis • 23 Feb 2021
What to look out for at ACTRIMS 2021 2:17
What to look out for at ACTRIMS 2021
Dalia Rotstein • 16 Feb 2021
Revising the neuromyelitis optica criteria 4:39
Revising the neuromyelitis optica criteria
Angela Vincent • 30 Oct 2020
Comorbidities in multiple sclerosis patients 3:33
Comorbidities in multiple sclerosis patients
Melinda Magyari • 2 Nov 2020
Initial high-efficacy disease-modifying therapy in multiple sclerosis 2:57
Initial high-efficacy disease-modifying therapy in multiple sclerosis
Melinda Magyari • 2 Nov 2020
Are MS patients at increased risk for developing cancer? 1:17
Are MS patients at increased risk for developing cancer?
Melinda Magyari • 2 Nov 2020
Neuromyelitis optica: new treatments and areas of development 7:45
Neuromyelitis optica: new treatments and areas of development
Brian Weinshenker • 26 Oct 2020
MS diagnosis: are the 2017 MS McDonald criteria too liberal? 6:41
MS diagnosis: are the 2017 MS McDonald criteria too liberal?
Brian Weinshenker • 26 Oct 2020
The problem with defining types of MS 3:10
The problem with defining types of MS
Gavin Giovannoni • 19 Oct 2020
The role of kynurenines in the pathogenesis of MS 3:25
The role of kynurenines in the pathogenesis of MS
Laszlo Vecsei • 28 Oct 2020
Understanding MS: PET imaging and microglial activity 3:19
Understanding MS: PET imaging and microglial activity
Laszlo Vecsei • 28 Oct 2020
The content of VJNeurology is intended for healthcare professionals